"I love Celularity Inc. (NASDAQ:CELU)"

2022-05-06 15:53:45

HomeCompanyColumn 1CompanyAbout UsCollaborationsLifebankManufacturingCompany BlogColumn 2Meet The TeamLeadershipBoard of DirectorsScientific AdvisorsCareersTour Our FacilityNewsroomPipelineThe PipelinePlacentaNK Cell PlatformT Cell PlatformExosomesExpanded Access PolicyInvestorsInvestor RelationsInvestor NewsroomStock InformationInvestor FAQsCorporate GovernanceSEC Filings MENU THE NEXTEVOLUTION INCELLULARMEDICINECelularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.COMPANY PIPELINEBEST IN CLASS & SCALABLECellular Medicine manufacturingFeaturing industry leading and diverse product linesALLOGENEIC PLATFORMBuilt on two decades of scienceDriven by a deep, seasoned management teamINNOVATIVE PLACENTA-DERIVEDT cells, NK Cells, and pluripotent stem cellsWith greater expandability, persistence, and stem-nessOUR MISSIONis to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economicsOUR VISIONHarness the Unique Biology & Ready Availability of the PlacentaUnmet Global NeedSignificant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelfGroundbreaking ResearchGroundbreaking basic & translational research into the unique biological activity of placental-derived cellsPioneering TechnologyPioneering technology platform of placental-derived cellular medicines and advanced biomaterialsIndustry TimingThe time has arrived for cellular medicines that overcome barriers of scale, quality, and economicsCelularity isCOMPANY PIPELINECellular Medicine ManufacturingThe Process is the ProductA fully integrated, purpose-built manufacturing, translational research and biobanking centerPurpose built facility staffed by over 100 highly specialized scientists, engineers & technicians150,000sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterialsClinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLETour Our FacilityThe Latest From OurNEWSROOM Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Celularity Inc Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference Celularity Inc Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers Celularity Inc Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers Celularity Inc Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.Meet Our Board of Directors (908) 768 - 2170Celularity Inc.170 Park AveFlorham Park, NJ 07932CompanyPipelineOur StoryLeadershipScientific AdvisorsBoard of DirectorsCareersSciencePlacentaNK Cell PlatformT Cell PlatformManufacturingLifebankBiovanceInvestorsInvestor RelationsInvestor NewsroomStock InformationCorporate GovernanceSEC FilingsInvestor FAQsCelularity Inc. © 2022. All rights reserved. NASDAQ:CELUPrivacy Policy     Terms & Conditions F.A.QSupport ForumVideo TutorialsSearch panel can contain any widgets and shortcodes.Call us: (908) 768 – 2170